Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Leukemia × eryaspase × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Triple Negative Breast Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia 1

Interventions

Imatinib Mesylate 19 Cytarabine 19 Cyclophosphamide 15 Azacitidine 15 venetoclax 14 nilotinib 14 fludarabine 13 Rituximab 10 blinatumomab 9 Dasatinib 9 quizartinib 7 Gemtuzumab 6 Daunorubicin 6 Clofarabine 6 Bendamustine Hydrochloride 6 ruxolitinib 5 ponatinib 5 fludarabine phosphate 5 Whole-Body Irradiation 5 Vincristine 5 Mycophenolic Acid 5 Methotrexate 5 Granulocyte Colony-Stimulating Factor 5 Drug Therapy 5 Dexamethasone 5 AP 1903 reagent 5 vosaroxin 4 revumenib 4 rasburicase 4 forodesine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01810705 2022-02-21

ENFORCE

ERYtech Pharma

Phase 2 Completed

123 enrolled 8 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡